Repositorio UFRO · Omeka S

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

Primer Autor	Eikelboom, John W.
Co-autores	Bosch, Jacqueline Connolly, Stuart J. Tyrwitt, Jessica Fox, Keith A. A. Muehlhofer, Eva Neumann, Christoph Tasto, Christoph Bangdiwala, Shrikant Diaz, Rafael Alings, Marco Dagenais, Gilles R. Leong, Darryl P. Lonn, Eva M. Avezum, Alvaro Piegas, Leopoldo S. Widimsky, Petr Parkhomenko, Alexander N. Bhatt, Deepak L. Branch, Kelley R. H. Probstfield, Jeffrey L. Lopez-Jaramillo, Patricio Ryden, Lars Pogosova, Nana Keltai, Katalin Keltai, Matyas Ertl, Georg Stoerk, Stefan Dans, Antonio L. Lanas, Fernando Liang, Yan Zhu, Jun Torp-Pedersen, Christian Maggioni, Aldo P. Commerford, Patrick J. Guzik, Tomasz J. Vanassche, Thomas Verhamme, Peter O'Donnell, Martin Tonkin, Andrew M. Varigos, John D. Vinereanu, Dragos Felix, Camillo Kim, Jae-Hyung Ibrahim, Khairul S. Lewis, Basil S. Metsarinne, Kaj P. Aboyans, Victor Steg, Phillippe Gabriel Hori, Masatsugu Kakkar, Ajay Anand, Sonia S. Lamy, Andre Sharma, Mukul Yusuf, Salim
Título	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
Editorial	OXFORD UNIV PRESS
Revista	EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
Lenguaje	en
Resumen	Aims To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE). Methods and results Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination. Conclusion In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
Fecha Publicación	2022
Tipo de Recurso	artículo original
Derecho de Acceso	acceso abierto
doi	10.1093/ehjcvp/pvac023
Formato Recurso	PDF
Palabras Claves	Coronary artery disease Peripheral artery disease Aspirin Rivaroxaban
Ubicación del archivo	http://dx.doi.org/10.1093/ehjcvp/pvac023
Categoría OCDE	Sistema cardiovascular y cardiología Farmacología y farmacia Sistema Cardiovascular y Cardiaco Farmacología y Farmacia
Materias	Arteriopatía coronaria Enfermedad de las arterias periféricas Aspirina Rivaroxabán
Página de inicio (Recomendado-único)	786.0
Página final (Recomendado-único)	795
Identificador del recurso (Mandatado-único)	artículo original
Versión del recurso (Recomendado-único)	versión publicada
Derechos de acceso	acceso abierto
Access Rights	acceso abierto
Id de Web of Science	WOS:000805292700001
ISSN	2055-6837
Tipo de ruta	verde# dorado
Categoría WOS	Sistema cardiovascular y cardiología Farmacología y farmacia